{"id":"W4405034776","doi":"10.1182/blood-2024-207816","title":"A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Antibody-drug conjugate; Medicine; Multiple myeloma; Refractory (planetary science); Phases of clinical research; Lenalidomide; Conjugate; Internal medicine; Pomalidomide; Oncology; Drug; Antibody; Pharmacology; Monoclonal antibody; Immunology; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001422016,0.001385258,0.001675351,0.0004941492,0.000488274,0.0009710717,0.001036745,0.001260245,0.002953462],"category_scores_gemma":[0.000748891,0.0005354566,0.001259893,0.0004853788,0.0009510008,0.0008438641,0.0003727633,0.003122364,0.001140392],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001193401,"about_ca_system_score_gemma":0.001506423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001112258,"about_ca_topic_score_gemma":0.002101496,"domain_scores_codex":[0.999529,0.0001874281,0.00002576592,0.0001011806,0.00004706164,0.0001096092],"domain_scores_gemma":[0.9993605,0.00006480241,0.00009707781,0.00006463009,0.00004985627,0.0003631591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.509342,0.1626649,0.02011755,0.0008652823,0.001776529,0.0006575292,0.0006737685,0.006884781,0.1368977,0.0006384532,0.009349899,0.1501316],"study_design_scores_gemma":[0.3272008,0.6344795,0.01940208,0.00002974715,0.000508246,0.0006300184,0.00008199177,0.002719455,0.009762431,0.0002250757,0.004919478,0.00004118891],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990342,0.001547661,0.0008979,0.0004863966,0.00009657561,0.002899975,0.001753328,0.000134819,0.001841365],"genre_scores_gemma":[0.9875902,0.0009153374,0.00267367,0.001099194,0.00009606334,0.002177438,0.003421685,0.00002901906,0.001997394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002953462,"threshold_uncertainty_score":0.009880364,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01677521466498579,"score_gpt":0.3028418557644812,"score_spread":0.2860666410994955,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}